C-Rad ABLTS:0R44 91 EV-to-FCF is 58.01 as of Jul. 08, 2026, which is 168% above its 10-year median of 21.63. GuruFocus rates LTS:0R44 with a GF Score™ of 91/100 and a GF Value™ of kr33.53 (Fairly Valued). The stock has 4 warning signs investors should review. Among 416 Medical Devices & Instruments companies, C-Rad AB ranks worse than 80.05% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, C-Rad AB's Enterprise Value is kr1,061.5 Mil.
C-Rad AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr18.3 Mil. Therefore, C-Rad AB's EV-to-FCF for today is 58.01.
The historical rank and industry rank for C-Rad AB's EV-to-FCF or its related term are showing as below:
LTS:0R44'
s EV-to-FCF Range Over the Past 10 Years
Min: -294.24 Med: 21.63 Max: 863.6
Current: 58.91
During the past 13 years, the highest EV-to-FCF of C-Rad AB was 863.60. The lowest was -294.24. And the median was 21.63.
LTS:0R44's EV-to-FCF is ranked worse than 80.05% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.515
vs LTS:0R44: 58.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C-Rad AB's share price for today is kr35.90.
C-Rad AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
C-Rad AB EV-to-FCF Related Terms
C-Rad AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for C-Rad AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, C-Rad AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where C-Rad AB's EV-to-FCF falls into.
C-Rad AB's current Enterprise Value is kr1,061.5 Mil.
C-Rad AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a EV-to-FCF of 58.01 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C-Rad AB and its competitors. This is 168% above median its historical median of 21.63. According to the industry distribution chart, C-Rad AB ranks #333 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 80%.
Is C-Rad AB's EV-to-FCF too high?
C-Rad AB's current EV-to-FCF of 58.01 is 168% above median its 10-year median of 21.63. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. C-Rad AB's value of 58.01 is 146.7% above this industry median. Based on the distribution chart, C-Rad AB ranks #333 out of 416 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, C-Rad AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #333 out of 416 companies for EV-to-FCF. This places C-Rad AB in the lower half of its industry. The industry median EV-to-FCF is 23.52. C-Rad AB's value of 58.01 is 146.7% above this benchmark. While the company's 10-year median is 21.63 vs. the industry median of 23.52, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current EV-to-FCF of 58.01 is 146.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current EV-to-FCF is 58.01, which is 168% above median its own 10-year median of 21.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.53, compared to a current price of kr35.90 — trading 7.1% above its estimated fair value. The current EV-to-FCF is 58.01, which is 168% above median its 10-year median of 21.63 and 146.7% above the Medical Devices & Instruments industry median of 23.52. C-Rad AB's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current EV-to-FCF is 58.01 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 7.1% above its estimated GF Value™ of kr33.53.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
EV-to-FCF: 58.01 (168% above median its 10-year median of 21.63)
GF Value™: kr33.53 vs. price of kr35.90 (7.1% above fair value)
Industry Position: 146.7% above the Medical Devices & Instruments median (#333 of 416)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
91GF Score
Get the complete analysis for LTS:0R44
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
